文献速递湿疹皮炎与荨麻疹

度普利尤单抗治疗红皮病型特应性皮炎患者的疗效与安全性:6项随机临床试验的事后分析

Efficacy and Safety of Dupilumab in Patients With Erythrodermic Atopic Dermatitis: A Post Hoc Analysis of 6 Randomized Clinical Trials.
PubMed 文献 · JAMA Dermatol · 2023-01-01

该事后分析纳入6项多中心、多国、随机、双盲、安慰剂对照试验中符合红皮病型特应性皮炎标准(BSA≥90%且红斑GISS≥1)的209例患者,评估度普利尤单抗每周一次或每2周一次(单药或联合外用糖皮质激素)第16周疗效与安全性。结果显示度普利尤单抗较安慰剂显著改善BSA受累百分比、EASI评分和PP-NRS评分,生物标志物显著降低,安全性可接受,与总体人群相似。

要点

  • 红皮病型AD患者中度普利尤单抗单药或联合TCS较安慰剂显著改善BSA、EASI和PP-NRS。
  • 单药治疗最早第1周即见EASI和PP-NRS评分名义统计学显著改善。
  • 最常见不良事件为注射部位反应、结膜炎和鼻咽炎。

核心结论

  • 在这项6项随机临床试验的事后分析中,度普利尤单抗治疗使红皮病型AD患者的体征和症状获得快速、持续改善,安全性可接受,与试验总体患者人群相似。

研究设计与样本

  • 事后分析纳入6项多中心、多国、随机、双盲、安慰剂对照试验中符合红皮病型AD标准(BSA≥90%且红斑GISS≥1)的患者。
  • 3075例随机患者中209例基线符合红皮病型AD标准,单药试验和联合TCS试验的中位年龄分别为31岁和39岁,总体人群分别为34岁和36岁。
  • 单药试验和联合TCS试验中男性分别占71.3%(n=97)和74.0%(n=54),总体人群分别为58.7%和60.6%。
  • 数据分析于2019年3月5日至2020年10月24日进行。

主要发现

  • 单药治疗组BSA受累百分比最小二乘均值变化(SE):每周一次-42.0%(7.7%)和每2周一次-39.9%(6.5%)vs 安慰剂-17.2%(11.0%),P=0.03。
  • 联合TCS组BSA受累百分比变化:每周一次-63.2%(6.7%)和每2周一次-56.1%(9.1%)vs 安慰剂-14.5%(7.3%),P<0.001。
  • 单药组EASI评分变化:每周一次-58.5%(9.0%)和每2周一次-58.3%(7.9%)vs 安慰剂-22.3%(12.4%),P=0.004和P=0.003。
  • 联合TCS组EASI评分变化:每周一次-78.9%(7.8%)和每2周一次-70.6%(10.1%)vs 安慰剂19.3%(8.2%),P<0.001。
  • 单药组PP-NRS评分变化:每周一次-45.9%(7.8%)和每2周一次-33.9%(6.6%)vs 安慰剂-0.6%(9.4%),P<0.001;联合TCS组分别为-53.0%(8.1%)和-55.7%(10.8%)vs 安慰剂-26.0%(8.8%),P=0.006和P=0.01。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Erythrodermic atopic dermatitis (AD) is a severe AD subtype defined by extensive skin involvement, leading to complications and sometimes hospitalization. OBJECTIVE: To assess dupilumab's efficacy and safety in patients with erythrodermic AD in clinical trials. DESIGN, SETTING, AND PARTICIPANTS: This post hoc analysis included patients enrolled in 6 multicenter, multinational, randomized, double-blind, placebo-controlled trials. Patients included in this analysis met erythrodermic AD criteria of 90% or greater body surface area (BSA) affected by AD and Global Individual Sign Score for erythema of 1 or higher. Data analyses for this post hoc analysis were conducted between March 5, 2019, and October 24, 2020. INTERVENTIONS: Dupilumab once weekly or every 2 weeks, or placebo, either as monotherapy or with concomitant topical corticosteroids (TCS). MAIN OUTCOMES AND MEASURES: Efficacy (BSA, Eczema Area and Severity Index [EASI] score, Peak Pruritus Numerical Rating Scale [PP-NRS] score), changes in serum biomarkers (thymus and activation-regulated chemokine, total immunoglobulin E, lactate dehydrogenase), and safety (incidence of adverse events) at week 16. Data were pooled within each regimen; monotherapy and concomitant TCS results are shown separately. RESULTS: Of 3075 randomized patients, 209 met criteria for erythrodermic AD at baseline, with the median age being 31 and 39 years in the monotherapy and concomitant TCS trials, respectively, similar to the overall populations (34 and 36 years, respectively); 71.3% (n = 97) and 74.0% (n = 54) of patients, respectively, were male (compared with 58.7% and 60.6% in the overall populations). In patients with erythrodermic AD, dupilumab once weekly and every 2 weeks vs placebo significantly improved percentage of BSA affected by AD (least squares mean percent change [SE]) with monotherapy (-42.0% [7.7%] and -39.9% [6.5%] vs -17.2% [11.0%]; P = .03) and concomitant TCS (-63.2% [6.7%] and -56.1% [9.1%] vs -14.5% [7.3%]; P < .001); EASI score with monotherapy (-58.5% [9.0%] and -58.3% [7.9%] vs -22.3% [12.4%]; P = .004 and P = .003, respectively) and concomitant TCS (-78.9% [7.8%] and -70.6% [10.1%] vs 19.3% [8.2%]; P < .001); and PP-NRS score in monotherapy (-45.9% [7.8%] and -33.9% [6.6%] vs -0.6% [9.4%]; P < .001) and concomitant therapy (-53.0% [8.1%] and -55.7% [10.8%] vs -26.0% [8.8%]; P = .006 and P = .01, respectively). Nominally statistically significant improvement was seen as early as week 1 (EASI and PP-NRS scores with monotherapy). Biomarker levels were significantly reduced vs placebo. The most frequent adverse events in dupilumab-treated patients were injection-site reaction, conjunctivitis, and nasopharyngitis. CONCLUSIONS AND RELEVANCE: In this post hoc analysis of 6 randomized clinical trials, treatment with dupilumab resulted in rapid, sustained improvements in AD signs and symptoms with acceptable safety in patients with erythrodermic AD, similar to those in the trials' overall patient population. TRIAL REGISTRATION: ClinicalTrials.gov Identifiers: NCT01859988, NCT02277743, NCT02277769, NCT03054428, NCT02260986, NCT02755649.

来源:JAMA Dermatol,查看原文。版权归原作者所有。

引用

  1. Paller AS, Silverberg JI, Cork MJ, et al. Efficacy and Safety of Dupilumab in Patients With Erythrodermic Atopic Dermatitis: A Post Hoc Analysis of 6 Randomized Clinical Trials. JAMA Dermatol. 2023. PMID: 36723913. doi:10.1001/jamadermatol.2022.6192

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。